Cencora, Inc. (COR) KPIs and segments
Close on Nov 17, 2026Market cap $66.90BP/E 26.0Yield 0.63%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Cencora · năm tài chính kết thúc ngày 30 tháng 9
Nhìn nhanh KPI của Cencora: 34 chỉ số vận hành, trong đó có Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services và Other, lấy từ 142 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Năm tài chính của Cencora kết thúc ngày 30 tháng 9 — Q4 FY26 = CQ3 2026 (quý dương lịch).
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
U.S. Healthcare Solutions($M) | 74,861 | 68,765 | 76,212 | 80,265 | 71,343 | 66,819 | 72,555 | 71,671 | 67,192 | 61,293 | 65,184 | ||
International Healthcare Solutions($M) | 7,680 | 7,566 | 7,624 | 9,457 | 7,253 | 6,697 | 6,959 | 7,382 | 7,052 | 7,123 | 7,070 | ||
Alliance Healthcare($M) | 6,601 | 6,516 | 6,531 | 6,230 | 5,772 | 5,999 | |||||||
Other Healthcare Solutions($M) | 1,079 | 1,049 | 1,093 | 1,023 | 925 | 960 | |||||||
U.S. Healthcare Solutions($M) | 966 | 998 | 831 | 1,109 | 834 | 945 | 687 | 697 | 698 | 841 | 698 | ||
International Healthcare Solutions($M) | 166 | 176 | 142 | 191 | 137 | 155 | 165 | 154 | 179 | 193 | 188 | ||
U.S. Healthcare Solutions($M) | 2,377 | 2,252 | 1,884 | 2,758 | 1,811 | 1,881 | 1,455 | ||||||
International Healthcare Solutions($M) | 822 | 814 | 789 | 1,099 | 736 | 716 | 764 | ||||||
International Healthcare Solutions($M) | -62.3 | -54.7 | -36.3 | -100 | -59.5 | -57.7 | -51.0 | ||||||
U.S. Healthcare Solutions($M) | -147 | -96.4 | -66.5 | -189 | -110 | -59.4 | -41.1 | ||||||
Pharmaceutical Distribution and Services — Revenue ($M)($M)4 | 74,242 | 71,164 | 66,108 | 72,969 | 71,352 | 67,701 | 63,351 | 69,442 | |||||
Pharmaceutical Distribution and Services — Segment Operating Income ($M)($M) | 691 | 664 | 775 | 607 | 615 | 591 | 726 | 569 | |||||
Pharmaceutical Distribution and Services — Gross Profit Margin (%)(%) | 2.3% | 2.4% | 2.7% | 2.3% | 2.3% | 2.3% | 2.6% | 2.3% | |||||
Pharmaceutical Distribution and Services — Operating Expense Ratio (% of Revenue)(%) | 1.4% | 1.5% | 1.5% | 1.4% | 1.4% | 1.5% | 1.5% | 1.5% | |||||
Pharmaceutical Distribution and Services — Operating Margin (%)(%) | 0.9% | 0.9% | 1.2% | 0.8% | 0.9% | 0.9% | 1.2% | 0.8% | |||||
Specialty Pharmaceutical and Provider Services — Revenue ($M)($M)4 | 12,175 | 11,645 | 10,471 | 11,099 | 10,542 | 11,137 | 10,419 | 10,490 | |||||
Specialty Pharmaceutical and Provider Services — Segment Operating Income ($M)($M) | 459 | 468 | 399 | 367 | 334 | 380 | 374 | 283 | |||||
Specialty Pharmaceutical and Provider Services — Gross Profit Margin (%)(%) | 12.6% | 12.9% | 12.3% | 9.2% | 9.2% | 8.7% | 9.0% | 6.1% | |||||
Specialty Pharmaceutical and Provider Services — Operating Expense Ratio (% of Revenue)(%) | 8.8% | 8.9% | 8.5% | 5.9% | 6.1% | 5.3% | 5.4% | 3.4% | |||||
Specialty Pharmaceutical and Provider Services — Operating Margin (%)(%) | 3.8% | 4.0% | 3.8% | 3.3% | 3.2% | 3.4% | 3.6% | 2.7% | |||||
Other (Revised 3-Segment Structure: European Distribution, Animal Health, Profarma & Consulting) — Revenue ($M)($M)7 | 2,302 | 2,253 | 2,056 | 2,129 | 2,092 | 2,108 | 1,956 | 2,003 | |||||
Other (Revised 3-Segment Structure) — Operating Income ($M)($M) | 101 | 109 | 91.6 | 91.4 | 74.4 | 87.1 | 92.9 | 97.3 | |||||
Other (Revised 3-Segment Structure) — Gross Profit Margin (%)(%) | 14.3% | 14.6% | 15.2% | 15.2% | 14.6% | 15.0% | 16.3% | 15.9% | |||||
Other (Revised 3-Segment Structure) — Operating Expense Ratio (% of Revenue)(%) | 9.9% | 9.8% | 10.7% | 11.0% | 11.0% | 10.8% | 11.5% | 11.0% | |||||
Other (Revised 3-Segment Structure) — Operating Margin (%)(%) | 4.4% | 4.8% | 4.5% | 4.3% | 3.6% | 4.1% | 4.8% | 4.9% | |||||
Intersegment Revenue Eliminations (Revised 3-Segment Structure, $M)($M) | -365 | -308 | -280 | -265 | -258 | -281 | -272 | -447 | |||||
Intersegment Operating Income Eliminations (Revised 3-Segment Structure, $M)($M) | -1.90 | -2.70 | -2.40 | -2.20 | 0 | -0 | 0 | 0 | |||||
Total Segment Operating Income (Revised 3-Segment Structure, $M)($M) | 1,249 | 1,238 | 1,263 | 1,063 | 1,023 | 1,058 | 1,192 | 949 | |||||
U.S. Healthcare Solutions — Segment Revenue ($M)($M)6 | 78,291 | 74,861 | 68,765 | 76,212 | 74,246 | 71,343 | 66,819 | 72,555 | 71,671 | 67,192 | 61,293 | 65,184 | |
Disaggregated Revenue: Animal Health (MWI Animal Health, $M)($M) | 1,520 | 1,436 | 1,471 | 1,472 | 1,363 | 1,380 | 1,402 | 1,370 | 1,309 | 1,286 | |||
U.S. Healthcare Solutions — Segment Cost of Goods Sold (ASU 2023-07, $M)($M) | 72,484 | 66,513 | 74,328 | 69,532 | 64,938 | 71,101 | |||||||
U.S. Healthcare Solutions — Segment Gross Profit Margin (%)(%) | 3.1% | 3.2% | 3.3% | 2.5% | 2.5% | 2.5% | 2.8% | 2.0% | 2.3% | 2.3% | 2.7% | 2.4% | |
U.S. Healthcare Solutions — Segment Operating Expenses (ASU 2023-07, $M)($M) | 1,410 | 1,254 | 1,052 | 978 | 936 | 768 | |||||||
U.S. Healthcare Solutions — Segment Operating Expense Ratio (% of Revenue)(%) | 1.9% | 1.9% | 1.8% | 1.4% | 1.4% | 1.4% | 1.4% | 1.1% | 1.3% | 1.3% | 1.4% | 1.3% | |
U.S. Healthcare Solutions — Segment Operating Margin (%)(%) | 1.3% | 1.3% | 1.5% | 1.1% | 1.1% | 1.2% | 1.4% | 1.0% | 1.0% | 1.0% | 1.4% | 1.1% | |
International Healthcare Solutions — Segment Revenue ($M)($M)9 | 7,798 | 7,681 | 7,566 | 7,624 | 7,420 | 7,253 | 6,697 | 6,959 | 7,382 | 7,052 | 7,123 | 7,070 | |
International Healthcare Solutions — Constant Currency Revenue YoY Growth (%)(%) | 7.8% | 6.1% | 7.2% | 6.2% | 5.7% | 8.8% | 5.7% | 8.5% | 7.9% | 5.8% | 9.8% | 8.7% | |
International Healthcare Solutions — Constant Currency Revenue ($M)($M) | 8,000 | 7,700 | 7,200 | 7,400 | 7,800 | 22,900 | 15,200 | 7,700 | 7,500 | 22,100 | 7,400 | 7,200 | |
International Healthcare Solutions — Segment Cost of Goods Sold (ASU 2023-07, $M)($M) | 6,858 | 6,752 | 6,835 | 6,518 | 5,981 | 6,195 | |||||||
International Healthcare Solutions — Segment Gross Profit Margin (%)(%) | 10.3% | 10.7% | 10.8% | 10.4% | 10.0% | 10.1% | 10.7% | 11.0% | 11.2% | 11.7% | 12.0% | 11.6% | |
International Healthcare Solutions — Segment Operating Expenses (ASU 2023-07, $M)($M) | 656 | 639 | 647 | 598 | 562 | 599 | |||||||
International Healthcare Solutions — Segment Operating Expense Ratio (% of Revenue)(%) | 8.3% | 8.5% | 8.4% | 8.5% | 8.2% | 8.3% | 8.4% | 8.6% | 9.1% | 9.1% | 9.2% | 8.9% | |
International Healthcare Solutions — Constant Currency Operating Income YoY Growth (%)(%) | 18.9% | 23.1% | 12.9% | -17.0% | -6.0% | -16.2% | -13.9% | 3.3% | -8.0% | 0.8% | 22.1% | 20.2% | |
International Healthcare Solutions — Constant Currency Operating Income ($M)($M) | 155 | 169 | 175 | 137 | 144 | 510 | 360 | 194 | 155 | 597 | 215 | 194 | |
International Healthcare Solutions — Segment Operating Margin (%)(%) | 2.0% | 2.2% | 2.3% | 1.9% | 1.8% | 1.9% | 2.3% | 2.4% | 2.1% | 2.5% | 2.7% | 2.7% | |
Other (FY2026 Segment Structure: MWI Animal Health, Profarma & PharmaLex) — Revenue ($M)($M)8 | 2,302 | 2,253 | 2,056 | 2,129 | 2,092 | 2,108 | 1,956 | 2,003 | |||||
Other — Disaggregated Revenue: Other Non-Strategic Businesses (Profarma & PharmaLex, $M)($M) | 734 | 620 | 658 | 636 | 593 | 623 | |||||||
Other — Segment Cost of Goods Sold (ASU 2023-07, $M)($M) | 1,925 | 1,744 | 1,805 | 1,792 | 1,638 | 1,685 | |||||||
Other — Segment Gross Profit ($M)($M) | 329 | 312 | 325 | 315 | 318 | 318 | |||||||
Other — Gross Profit Margin (%)(%) | 14.3% | 14.6% | 15.2% | 15.2% | 14.6% | 15.0% | 16.3% | 15.9% | |||||
Other — Segment Operating Expenses (ASU 2023-07, $M)($M) | 220 | 220 | 233 | 228 | 226 | 220 | |||||||
Other — Operating Expense Ratio (% of Revenue)(%) | 9.9% | 9.8% | 10.7% | 11.0% | 11.0% | 10.8% | 11.5% | 11.0% | |||||
Other — Segment Operating Income ($M)($M) | 101 | 109 | 91.6 | 91.4 | 74.4 | 87.1 | 92.9 | 97.3 | |||||
Other — Segment Operating Margin (%)(%) | 4.4% | 4.8% | 4.5% | 4.3% | 3.6% | 4.1% | 4.8% | 4.9% | |||||
Total Segment Operating Income (Pre-Reconciliation Subtotal, $M)($M)3 | 1,249 | 1,238 | 1,263 | 1,063 | 1,023 | 1,058 | 1,192 | 949 | 851 | 878 | 1,034 | 886 | |
Intersegment Revenue Eliminations ($M)($M) | -36.8 | -39.7 | -30.5 | -32.7 | -29.7 | -40.2 | -18.8 | -29.6 | -3.10 | -2.10 | -2 | -1.20 | |
Consolidated Cost of Goods Sold (ASU 2023-07 Segment Footnote Total, $M)($M) | 81,232 | 74,982 | 82,939 | 77,803 | 72,539 | 78,952 | |||||||
Total Segment Operating Expenses (ASU 2023-07 Segment Footnote Total, $M)($M) | 2,285 | 2,111 | 1,931 | 1,802 | 1,723 | 1,586 | |||||||
GLP-1 Medications (Diabetes / Weight-Loss) — YoY Revenue Increase ($M)($M)2 | 2,800 | 2,300 | 1,900 | 1,000 | 876 | 1,400 | 2,200 | 3,200 | 3,100 | 2,100 | 1,300 | 2,100 | |
Manufacturer List Price Reductions — YoY Revenue Headwind ($M)($M) | 2,800 | 2,400 | 2,000 | ||||||||||
Sales to Two Largest Customers (Walgreens & Evernorth) — YoY Revenue Increase ($M, FY2023–FY2025)($M) | 600 | 1,400 | 800 | 3,300 | 3,500 | 2,000 | 2,500 | 3,200 | |||||
Working Capital Efficiency: Days Sales Outstanding (DSO, Days)(ngày)2 | 27 | 28 | 28 | 28 | 28 | 28 | 29 | 30 | 28 | ||||
Days Inventory on Hand (DIO, Days)(ngày) | 27 | 30 | 28 | 27 | 29 | 26 | 26 | 28 | 27 | ||||
Days Payable Outstanding (DPO, Days)(ngày) | 60 | 65 | 59 | 59 | 61 | 59 | 60 | 62 | 60 | ||||
Right to Recover Assets (Merchandise Returns Inventory Asset, $M)($M)2 | 1,277 | 1,569 | 1,575 | 1,662 | 1,626 | 1,431 | 1,302 | 1,193 | 1,176 | 1,144 | 1,195 | 1,243 | |
LIFO Expense / (Credit) Pre-Tax Charge ($M)($M) | -5.60 | -94.3 | -210 | -77.6 | -57 | -52.1 | 39.5 | -7.30 | 12.3 | 6.80 | -22.8 | -48.4 | |
Allowance for Doubtful Accounts / Expected Credit Losses ($M)($M) | 1,735 | 1,711 | 1,835 | 1,796 | 1,593 | 1,438 | 1,327 | 1,308 | 1,271 | 1,331 | 1,371 | ||
Non-GAAP Adjusted Operating Income ($M)($M)12 | 1,249 | 1,238 | 1,263 | 1,063 | 1,023 | 1,058 | 1,192 | 949 | 851 | 878 | 1,034 | 886 | |
Non-GAAP Adjusted Gross Profit ($M)($M) | 3,572 | 3,523 | 3,374 | 2,993 | 2,904 | 2,860 | 2,915 | 2,535 | 2,453 | 2,370 | 2,530 | 2,389 | |
Non-GAAP Adjusted Operating Expenses ($M)($M) | 2,323 | 2,285 | 2,111 | 1,931 | 1,881 | 1,802 | 1,723 | 1,586 | 1,602 | 1,492 | 1,496 | 1,504 | |
Non-GAAP Adjusted Income Before Income Taxes ($M)($M) | 1,123 | 1,102 | 1,131 | 994 | 956 | 989 | 1,090 | 917 | 836 | 852 | 968 | 840 | |
Non-GAAP Adjusted Income Tax Expense ($M)($M) | 227 | 219 | 214 | 189 | 197 | 205 | 227 | 183 | 169 | 179 | 202 | 176 | |
Non-GAAP Adjusted Net Income Attributable to Cencora, Inc. ($M)($M) | 893 | 869 | 928 | 797 | 751 | 781 | 863 | 728 | 662 | 668 | 765 | 661 | |
Non-GAAP Adjusted Diluted Earnings Per Share ($/Share)($) | 4.66 | 4.48 | 4.75 | 4.08 | 3.84 | 4 | 4.42 | 3.73 | 3.34 | 3.34 | 3.80 | 3.28 | |
Non-GAAP Adjusted Gross Profit Margin (%)(%) | 4.0% | 4.2% | 4.3% | 3.5% | 3.5% | 3.6% | 3.9% | 3.1% | 3.1% | 3.2% | 3.7% | 3.3% | |
Non-GAAP Adjusted Operating Expense Ratio (% of Revenue)(%) | 2.6% | 2.7% | 2.7% | 2.3% | 2.3% | 2.2% | 2.3% | 2.0% | 2.0% | 2.0% | 2.2% | 2.1% | |
Non-GAAP Adjusted Operating Margin (%)(%) | 1.4% | 1.5% | 1.6% | 1.2% | 1.2% | 1.3% | 1.6% | 1.2% | 1.1% | 1.2% | 1.5% | 1.2% | |
Consolidated GAAP Gross Profit Margin (%)(%) | 4.1% | 4.3% | 4.6% | 3.6% | 3.5% | 3.6% | 4.1% | 3.1% | 3.2% | 3.3% | 3.7% | 3.4% | |
Consolidated GAAP Operating Expense Ratio (% of Revenue)(%) | 3.1% | 2.9% | 3.1% | 2.7% | 3.5% | 2.5% | 2.7% | 2.3% | 3.0% | 2.3% | 2.9% | 2.3% | |
Consolidated GAAP Operating Margin (%)(%) | 1.0% | 1.3% | 1.5% | 0.9% | 0.0% | 1.1% | 1.4% | 0.9% | 0.2% | 0.9% | 0.8% | 1.1% | |
Pre-Tax Non-GAAP Adjustment: Acquisition-Related Intangibles Amortization ($M)($M)6 | 116 | 117 | 116 | 125 | 126 | 125 | 137 | 165 | 166 | 164 | 165 | 166 | |
Pre-Tax Adjustment: Litigation & Opioid-Related Expenses / (Credit), Net ($M)($M) | 12.1 | -88.6 | 13.9 | -86.2 | 14.4 | 18 | 11.5 | 16.8 | 65.5 | 14.5 | 226 | -78.9 | |
Accrued Opioid & Litigation Liability — Noncurrent Balance ($M)($M) | 3,670 | 3,774 | 3,857 | 3,869 | 3,881 | 4,285 | 4,285 | 4,297 | 4,297 | 4,698 | 4,720 | 4,732 | |
Pre-Tax Adjustment: Acquisition & Divestiture-Related Deal and Integration Expenses ($M)($M) | 177 | 113 | 164 | 78.4 | 100 | 52.8 | 99.4 | 38.7 | 33.6 | 25.8 | 22.6 | 21.1 | |
Pre-Tax Adjustment: Restructuring & Other Expenses ($M)($M) | 65.1 | 60.6 | 40.9 | 14.2 | 89 | 41.8 | 52.9 | 45.8 | 81.3 | 42.3 | 75.6 | 34.4 | |
Pre-Tax Adjustment: Gains from Antitrust Litigation Settlements ($M)($M) | -38.4 | -5.50 | -16.5 | -12.2 | -5.40 | -9.50 | -199 | -22.9 | -62.3 | -51.6 | -8.70 | -48.2 | |
Pre-Tax Adjustment: Türkiye Highly Inflationary Accounting Impact ($M)($M) | 15.4 | 15.4 | 12.2 | 10.9 | 13.2 | 14.8 | 14.5 | 7.20 | 10.2 | 3.60 | 23.1 | 17.2 | |
Non-GAAP Adjusted Free Cash Flow ($M)($M) | 2,666 | 2,423 | 1,157 | -2,437 | 2,878 | -83.5 | 3,024 | -2,848 | 756 | 763 | |||
Consolidated Constant Currency Revenue ($M)($M)1 | 88,600 | 84,800 | 78,000 | 85,700 | 83,600 | 238,100 | 157,500 | 81,700 | 79,200 | 215,700 | 68,700 | 72,400 | |
Consolidated Constant Currency Adjusted Operating Income ($M)($M) | 1,252 | 1,241 | 1,262 | 1,058 | 1,000 | 3,212 | 2,160 | 961 | 852 | 2,835 | 1,100 | 892 | |
U.S. Federal Government Contract Obligations to Cencora / AmerisourceBergen (VA / DoD / HHS, $M)($M) | 543 | 2,141 | 2,090 | 1,811 | 2,099 | 1,881 | 1,807 | 1,647 | 1,836 | 1,190 | 757 | 578 | |
Peer Benchmark: McKesson Corporation (MCK) — Consolidated Revenue ($M)($M)2 | 105,380 | 106,158 | 103,150 | 97,827 | 95,294 | 93,651 | 79,283 | 80,898 | |||||
McKesson (MCK) — Consolidated Gross Profit ($M)($M) | 3,685 | 3,685 | 3,542 | 3,279 | 3,284 | 3,248 | 3,152 | 3,152 | |||||
McKesson (MCK) — Consolidated GAAP Operating Income ($M)($M) | 1,319 | 1,619 | 1,407 | 1,036 | 1,224 | 578 | 1,029 | 642 | |||||
Peer Benchmark: Cardinal Health, Inc. (CAH) — Consolidated Revenue ($M)($M)2 | 65,627 | 64,009 | 54,878 | 55,264 | 52,277 | 54,868 | 57,442 | ||||||
Cardinal Health (CAH) — Consolidated Gross Profit ($M)($M) | 2,397 | 2,319 | 2,123 | 1,941 | 1,902 | 1,935 | 1,854 | ||||||
Cardinal Health (CAH) — Consolidated GAAP Operating Income/(Loss) ($M)($M) | 707 | 668 | 730 | 549 | 568 | 369 | 505 | ||||||
Peer Benchmark: Option Care Health, Inc. (OPCH) — Consolidated Revenue ($M)($M)2 | 1,442 | 1,351 | 1,435 | 1,416 | 1,333 | 1,279 | 1,227 | 1,146 | |||||
Consolidated Revenue (GAAP, $M)($M)15 | 88,355 | 84,755 | 78,356 | 85,932 | 83,729 | 80,664 | 75,454 | 81,487 | 79,050 | 74,241 | 68,414 | 72,253 | |
Cost of Goods Sold (GAAP, $M)($M) | 84,754 | 81,148 | 74,768 | 82,860 | 80,775 | 77,756 | 72,394 | 78,929 | 76,558 | 71,831 | 65,876 | 69,784 | |
Gross Profit (GAAP, $M)($M) | 3,601 | 3,607 | 3,588 | 3,072 | 2,954 | 2,907 | 3,060 | 2,558 | 2,492 | 2,411 | 2,538 | 2,469 | |
Distribution, Selling & Administrative Expenses (GAAP, $M)($M) | 2,173 | 2,133 | 1,978 | 1,795 | 1,749 | 1,673 | 1,600 | 1,472 | 1,490 | 1,383 | 1,389 | 1,399 | |
Total Operating Expenses (GAAP, $M)($M) | 2,694 | 2,285 | 2,111 | 1,931 | 1,881 | 1,802 | 1,723 | 1,586 | |||||
Restructuring & Other Expenses, Net (GAAP Income Statement, $M)($M) | 65.1 | 60.6 | 40.9 | 14.2 | 89 | 41.8 | 52.9 | 45.8 | 81.3 | 42.3 | 75.6 | 34.4 | |
Litigation & Opioid-Related Expenses / (Credit), Net (GAAP Income Statement, $M)($M) | 12.1 | 5.50 | 16.5 | 12.2 | 5.40 | 9.50 | 199 | 22.9 | 62.3 | 51.6 | 8.70 | 48.2 | |
Operating Income (GAAP, $M)($M) | 907 | 1,120 | 1,143 | 760 | 18.5 | 868 | 1,036 | 706 | 127 | 673 | 553 | 823 | |
Income Before Income Taxes (GAAP, $M)($M) | 787 | 996 | 2,089 | 709 | -187 | 896 | 929 | 620 | 125 | 628 | 467 | 783 | |
Income Tax Expense (GAAP, $M)($M) | 258 | 220 | 459 | 143 | 146 | 207 | 211 | 127 | 118 | 141 | 45.9 | 180 | |
Net Income Including Noncontrolling Interests (GAAP, $M)($M) | 529 | 777 | 1,630 | 566 | -333 | 690 | 717 | 494 | 7.50 | 488 | 421 | 603 | |
Net Income Attributable to Cencora, Inc. (GAAP, $M)($M) | 519 | 764 | 1,641 | 560 | -340 | 687 | 718 | 489 | 3.40 | 484 | 421 | 602 | |
Diluted Earnings Per Share (GAAP, $/Share)($) | 2.71 | 3.94 | 8.40 | 2.87 | 3.52 | 3.68 | 2.50 | 2.42 | 2.09 | 2.98 | |||
Basic Earnings Per Share (GAAP, $/Share)($) | 2.72 | 3.95 | 8.44 | 2.88 | 3.55 | 3.70 | 2.52 | 2.44 | 2.11 | 3.01 | |||
Diluted Weighted-Average Common Shares (Millions)(M) | 192 | 194 | 195 | 195 | 195 | 195 | 195 | 200 | 201 | 202 | |||
Basic Weighted-Average Common Shares (Millions)(M) | 191 | 193 | 195 | 194 | 194 | 194 | 194 | 198 | 199 | 200 | |||
Total Assets (GAAP, $M)($M)13 | 87,105 | 83,806 | 81,652 | 78,361 | 76,590 | 73,957 | 71,194 | 69,054 | 67,102 | 66,772 | 63,868 | 64,690 | |
Cash & Cash Equivalents ($M)($M) | 4,880 | 2,815 | 2,177 | 1,753 | 4,356 | 2,232 | 1,978 | 3,224 | 3,133 | 3,306 | 2,069 | 2,872 | |
Accounts Receivable, Net ($M)($M) | 26,334 | 25,448 | 24,893 | 25,980 | 25,225 | 24,562 | 23,715 | 24,546 | 23,872 | 24,052 | 22,643 | 21,577 | |
Merchandise Inventories ($M)($M) | 21,364 | 21,030 | 20,010 | 24,079 | 20,493 | 20,138 | 18,966 | 20,508 | 18,999 | 18,302 | 17,631 | 18,652 | |
Prepaid Expenses & Other Current Assets ($M)($M) | 697 | 636 | 637 | 678 | 539 | 451 | 575 | 516 | 539 | 460 | 512 | 493 | |
Total Current Assets ($M)($M) | 58,452 | 55,335 | 53,141 | 54,152 | 52,239 | 48,814 | 46,535 | 49,987 | 47,718 | 47,307 | 44,161 | 44,859 | |
Property & Equipment, Net ($M)($M) | 3,039 | 2,838 | 2,805 | 2,451 | 2,539 | 2,431 | 2,303 | 2,100 | 2,181 | 2,081 | 2,090 | 2,117 | |
Other Long-Term Assets ($M)($M) | 3,134 | 3,007 | 3,006 | 4,143 | 4,153 | 4,228 | 4,168 | 3,889 | 3,637 | 3,530 | 3,566 | 3,459 | |
Accounts Payable ($M)($M) | 58,011 | 54,700 | 51,882 | 56,064 | 54,720 | 51,044 | 50,111 | 49,911 | 50,942 | 49,883 | 46,321 | 47,744 | |
Accrued Expenses & Other Current Liabilities ($M)($M) | 3,260 | 3,349 | 3,196 | 2,726 | 2,983 | 2,717 | 2,448 | 2,385 | 2,759 | 2,526 | 2,372 | 2,437 | |
Total Current Liabilities ($M)($M) | 62,381 | 59,197 | 56,132 | 59,132 | 57,821 | 53,958 | 53,328 | 54,509 | 54,277 | 52,974 | 49,762 | 50,774 | |
Long-Term Debt ($M)($M) | 11,063 | 11,444 | 12,183 | 7,580 | 7,543 | 8,044 | 7,086 | 5,935 | 3,812 | 4,166 | 4,180 | 4,186 | |
Other Long-Term Liabilities ($M)($M) | 4,155 | 3,969 | 3,795 | 3,698 | 3,640 | 3,540 | 3,422 | 2,062 | 1,994 | 1,934 | 1,962 | 1,912 | |
Total Stockholders' Equity / (Deficit) ($M)($M) | 3,681 | 3,239 | 3,585 | 2,096 | 1,747 | 2,210 | 1,180 | 362 | 787 | 1,061 | 1,227 | 1,061 | |
Operating Cash Flow (GAAP, $M)($M)7 | 3,103 | 2,654 | 1,339 | -2,305 | 3,133 | 109 | 3,351 | -2,719 | 1,000 | 2,478 | -878 | 885 | |
Capital Expenditures (Additions to Property & Equipment, $M)($M) | 399 | 226 | 166 | 119 | 250 | 183 | 129 | 106 | 182 | 118 | 113 | 74.2 | |
Cost of Acquired Companies, Net of Cash Acquired ($M)($M) | -20.9 | -41.7 | -4,712 | -220 | -91.4 | -56.5 | -3,939 | -9 | -45.3 | -22.2 | -2.30 | 0 | |
Net Cash Used in Investing Activities (GAAP, $M)($M) | -386 | -240 | -4,875 | -299 | -322 | -235 | -4,078 | -343 | -242 | -144 | -167 | -65.8 | |
Purchases of Common Stock (Cash Flow Statement Outflow, $M)($M) | 0 | 1,000 | -0 | -0 | -0 | -0 | 50 | 386 | 505 | 550 | 50.8 | 386 | |
Cash Dividends Paid on Common Stock ($M)($M) | 116 | 117 | 118 | 127 | 108 | 108 | 111 | 111 | 101 | 103 | 107 | 106 | |
Net Cash Provided by / (Used in) Financing Activities (GAAP, $M)($M) | -601 | -1,768 | 3,979 | 43.2 | -684 | 216 | -492 | 3,209 | -957 | -1,145 | 323 | -552 | |
Net Change in Cash, Cash Equivalents & Restricted Cash ($M)($M) | 2,107 | 629 | 428 | -2,586 | 2,119 | 96.8 | -1,216 | 97.1 | -179 | 1,191 | -751 | 283 | |
18 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Revised 3-Segment Reporting Structure (effective FY2027, restated across FY2025Q1–FY2026Q4 and FY2025–FY2026 in Form 8-K Exhibit 99.1 filed November 4, 2026) disaggregates Cencora into Pharmaceutical Distribution and Services ($284,484.2M revenue and $2,736.4M operating income in FY2026), Specialty Pharmaceutical and Provider Services ($45,356.3M revenue and $1,693.0M operating income in FY2026, encompassing U.S. specialty distribution, OneOncology, Retina Consultants of America, World Courier, and Innomar), and Other ($9,613.2M revenue and $392.9M operating income in FY2026; Intersegment operating income eliminations of -$9.2M).
- Historical 2-Segment + Other structure (U.S. Healthcare Solutions, International Healthcare Solutions, and Other across 24 quarters FY2021Q1–FY2026Q4 and 6 fiscal years FY2021–FY2026) is enriched with ASC 606 disaggregated revenue (Human Health, Animal Health / MWI, Alliance Healthcare European Distribution, Other International Healthcare Solutions, and Other Non-Strategic Businesses across 28 periods), ASU 2023-07 significant segment expenses (Segment Cost of Goods Sold and Segment Operating Expenses), MD&A Segment Gross Profit, Constant Currency YoY growth rates, and legacy pre-FY2021Q4 segment history.
- Operational, working capital, and balance-sheet drivers extracted from Form 10-K/10-Q MD&A, Footnotes, and Earnings Releases include GLP-1 medications YoY revenue increases (+$2,800M in Q4 FY2026, +$8,900M in FY2025, +$8,600M in FY2024, +$5,400M in FY2023), manufacturer list price reduction revenue headwinds ($2,000M–$2,800M per quarter in Q2–Q4 FY2026), Working Capital Turnover Days (Days Sales Outstanding 27.1 days, Days Inventory on Hand 26.6 days, Days Payable Outstanding 59.7 days in Q3 FY2026 across 30 periods), Right to Recover customer return assets ($1,276.5M in Q4 FY2026), LIFO inventory reserves ($1,458.9M in FY2025), noncurrent accrued opioid litigation liabilities ($3,670.1M in Q4 FY2026), Walgreens Boots Alliance (26%) & Evernorth (13%) customer concentration, consolidated Brazil VIE (Profarma) balance sheet series, ASC 842 operating lease metrics, and 90 consecutive months of share repurchases (October 2018–June 2026).
- Only directly reported point figures and cumulative year-to-date period splits (`Q4 = full year − nine months` on ASC 606 disaggregated revenue, ASU 2023-07 segment costs, MD&A segment gross profit, GLP-1 / top-2 customer YoY increases, and GAAP cash flows) are included; no self-computed ratios, margins, or growth rates are added. Consolidated-minus-standalone parent subtraction is not applicable because Cencora, Inc. files consolidated U.S. GAAP financial statements on Form 10-K without standalone parent-company operating revenue.
- Metrics disclosed only as approximate bounds in recent periods (Total global headcount 'more than 46,000' in FY2024 and 'more than 51,000' in FY2025; Good Neighbor Pharmacy network 'more than 4,800 / nearly 5,000' pharmacies; single-event MSO acquisition provider bounds) are excluded from active series and documented in `excluded`.
Không hiện vì thiếu các kỳ gần đây (5)
- Global Workforce & Human Capital › Total Employees Worldwide (FY2024–FY2025) — Disclosed only as bounds ('more than 46,000' in FY2024 and 'more than 51,000' in FY2025) in Form 10-K Item 1; Full-Time Employees (47,000 in FY2025) is retained as an exact/approximate series, and FY2019–FY2023 Total Employees is retained as a legacy series
- Distribution & MSO Network › Good Neighbor Pharmacy / Elevate Provider Network Member Pharmacies — Disclosed only as bounds ('more than 4,800', 'nearly 5,000', or 'thousands of independent community pharmacies') in Form 10-K and ESG reports
- Management Services Organizations (MSOs) › OneOncology, Retina Consultants of America (RCA) & American Oncology Network (AON) Provider / Clinic Counts — Disclosed as single-event acquisition bounds ('more than 350 oncology providers across 21 states' for AON; 'nearly 300 retinal physicians across 250+ locations' for RCA) in Form 8-K press releases
- ESG & Operations › Daily Healthcare Products Shipped & Global Operating Locations — Disclosed only as bounds ('more than 6.7 million healthcare products daily', '1,300+ locations', '50+ countries') in Corporate Responsibility Reports
- ESG & Operations › Occupational Safety Total Recordable Incident Rate (TRIR) & DART — Narrative safety program disclosures in FY2025 Corporate Responsibility Report (GRI 403-9) without a multi-year quantitative rate table
Dữ liệu cập nhật 2026-11-07.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Reportable Segments — Revised 3-Segment Structure (Effective FY2027; Restated FY2025Q1–FY2026Q4 & FY2025–FY2026)
Reportable Segments — U.S. & International Healthcare Solutions, ASC 606 Disaggregated Revenue & ASU 2023-07 Costs
- U.S. Healthcare Solutions — Segment Revenue ($M) ($M)24 kỳ
- International Healthcare Solutions — Segment Revenue ($M) ($M)24 kỳ
- Other (FY2026 Segment Structure: MWI Animal Health, Profarma & PharmaLex) — Revenue ($M) ($M)8 kỳ
- Total Segment Operating Income (Pre-Reconciliation Subtotal, $M) ($M)35 kỳ
- Pharmaceutical Distribution Services (Legacy Segment Pre-Q4 FY2021 Realignment) — Revenue ($M) ($M)17 kỳ
- Other: Global Commercialization Services & Animal Health (Legacy Segment Pre-Q4 FY2021) — Revenue ($M) ($M)17 kỳ
U.S. Healthcare Operational & Therapeutic Growth Drivers (GLP-1), Working Capital Efficiency (DSO/DIO/DPO) & Reserves
Customer & Supplier Concentration, Workforce, Brazil VIE (Profarma), ASC 842 Leases, Tax Geography & Monthly Share Repurchases
- Largest Customer: Walgreens Boots Alliance (WBA) — Share of Consolidated Revenue (%) (%)7 kỳ
- Full-Time Employees Worldwide (Headcount)7 kỳ
- Consolidated Brazil Subsidiary VIE (Profarma Distribuidora) — Total Assets ($M) ($M)8 kỳ
- Operating Lease Right-of-Use (ROU) Assets ($M) ($M)6 kỳ
- Consolidated Income Before Income Taxes (Geographic Tax Footnote Total, $M) ($M)8 kỳ
- Monthly Common Shares Repurchased — Total (Shares)90 kỳ
Consolidated Non-GAAP Profitability, Pre-Tax Adjustments, Opioid Litigation Reserve & Constant Currency
ESG Climate & Waste Footprint, U.S. Federal Contract Obligations (USAspending), Pharmaceutical Wholesale Macro (FRED) & Peer Benchmarks
- ESG Climate Footprint: Scope 1 Direct Greenhouse Gas Emissions (Metric Tons CO2e)5 kỳ
- U.S. Federal Government Contract Obligations to Cencora / AmerisourceBergen (VA / DoD / HHS, $M) ($M)106 kỳ
- U.S. Merchant Wholesalers Sales: Drugs & Druggists' Sundries (NAICS 4242, $M) ($M)103 kỳ
- U.S. Retail Sales: Pharmacies & Drug Stores (NAICS 44611, $M) ($M)104 kỳ
- U.S. Producer Price Index (PPI): Pharmaceutical Preparations (Index) (×)105 kỳ
- Peer Benchmark: McKesson Corporation (MCK) — Consolidated Revenue ($M) ($M)67 kỳ
- Peer Benchmark: Cardinal Health, Inc. (CAH) — Consolidated Revenue ($M) ($M)64 kỳ
- Peer Benchmark: Option Care Health, Inc. (OPCH) — Consolidated Revenue ($M) ($M)52 kỳ
Consolidated GAAP Financial Statements & XBRL Segment Baseline
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Cencora
- Cencora Form 8-K (FY2026Q4) — Q4 FY2026 Earnings Release (Exhibit 99.1) ↗
- Cencora Form 10-K (filed 2025-11-25, acc 0001140859-25-000131) ↗
- Cencora Form 8-K (filed 2026-11-04, acc 0001140859-26-000038) ↗
- Cencora Form 8-K (filed 2026-11-04, acc 0001140859-26-000040) ↗
- Cencora Form 8-K (FY2021Q4) — Q4 FY2021 Earnings Release (Exhibit 99.1) ↗
- USAspending.gov Federal Contract Awards — Cencora, Inc. / AmerisourceBergen ↗
- Cencora Form 10-Q (filed 2026-08-05, acc 0001140859-26-000034) ↗
- SEC EDGAR XBRL CompanyFacts (MCK) ↗
- SEC EDGAR XBRL CompanyFacts (CAH) ↗
- SEC EDGAR XBRL CompanyFacts (OPCH) ↗
- Cencora Q4 FY2026 Earnings Call Transcript (2026-11-04) — CFO Prepared Remarks ↗
- Cencora Form 8-K (filed 2025-11-05, acc 0001140859-25-000128) ↗
See a number that looks wrong?